Picture loading failed.

Anti-IGF1R therapeutic antibody (Pre-made Teprotumumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

A recombinant, fully human monoclonal antibody directed against the insulin-like growth factor-1 receptor (IGF-1R) with potential antineoplastic activity.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-564-1mg 1mg 3090
GMP-Bios-ab-564-10mg 10mg 21890
GMP-Bios-ab-564-100mg 100mg 148000
GMP-Bios-ab-564-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-IGF1R therapeutic antibody (Pre-made Teprotumumab biosimilar,Whole mAb)
INN Name Teprotumumab
TargetIGF1R
FormatWhole mAb
DerivationHuman
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2009
Year Recommended2010
CompaniesGenmab;Roche;Horizon Therapeutics plc
Conditions ApprovedGraves ophthalmopathy
Conditions ActiveDiffuse scleroderma
Conditions DiscontinuedDiabetic macular oedema;Advanced breast cancer;Hodgkin's disease;Non-Hodgkin's lymphoma;Non-small cell lung cancer;Sarcoma;Solid tumours
Development TechMedarex UltiMAb Mouse